Last updated: October 17, 2026
XROMI is a pediatric oral hydroxycarbamide formulation for preventing recurrent painful vaso-occlusive crises in patients with sickle cell anemia. Its commercial opportunity is concentrated in specialist pediatric hematology rather than broad primary care. Public disclosures do not report standalone XROMI revenue, operating profit, or unit sales, so its financial trajectory must be assessed through market access, patient expansion, formulation differentiation, and competitive pressure.
The product’s main commercial strengths are liquid administration, pediatric suitability, and alignment with long-term hydroxycarbamide therapy. Its constraints are a narrow indication, low visibility outside specialist care, reimbursement dependence, competition from compounded liquid formulations and capsules, and limited evidence of large-scale geographic expansion.
What is XROMI and who markets it?
XROMI contains hydroxycarbamide, also known as hydroxyurea, at a concentration of 100 mg/mL in an oral solution. It is used in children from two years of age with sickle cell anemia to prevent recurrent painful vaso-occlusive crises. The product is particularly relevant for children who cannot reliably swallow capsules or require weight-based dose adjustments.
| Attribute |
XROMI |
| Active ingredient |
Hydroxycarbamide |
| Strength |
100 mg/mL oral solution |
| Therapeutic area |
Sickle cell disease |
| Primary use |
Prevention of recurrent painful vaso-occlusive crises |
| Patient segment |
Pediatric patients, generally age 2 years and older |
| Dosage form |
Oral liquid |
| Regulatory region |
United Kingdom and selected European markets |
| Product type |
Specialist, orphan-designated medicine |
| U.S. FDA status |
No established U.S. approval identified in the cited regulatory records |
| Public standalone revenue |
Not disclosed |
XROMI has been associated with Nova Laboratories and its European commercialization activities. Regulatory ownership and marketing authorization structures can differ by territory, particularly after the United Kingdom’s separation from the European Union regulatory system. The product is sold through specialist channels rather than mass-market pharmacy distribution.
What is the FDA regulatory status of XROMI?
XROMI is not an FDA-approved product based on the U.S. regulatory sources reviewed for this analysis. Its commercial footprint is therefore centered on the United Kingdom and European markets rather than the United States.
The absence of a U.S. approval has two effects. First, XROMI does not participate directly in the much larger U.S. sickle cell pharmaceutical market. Second, the product avoids immediate U.S. generic competition but also loses access to the market with the greatest commercial potential for sickle cell therapies.
In the United Kingdom, XROMI is regulated as a prescription medicine for specialist use. Its regulatory value comes from an authorized pediatric formulation of an established active ingredient, not from a new molecular entity.
How large is the market opportunity for XROMI?
XROMI operates in a growing but specialized sickle cell market. Demand is driven by four structural factors:
- Rising diagnosis and survival of patients with sickle cell disease.
- Greater use of disease-modifying therapy in children.
- Improved adherence from age-appropriate liquid formulations.
- Expansion of specialist pediatric hematology services.
The addressable market is much smaller than the total sickle cell drug market because XROMI is concentrated in pediatric patients requiring hydroxycarbamide oral solution. Capsules, tablets, extemporaneously compounded liquids, and other hydroxyurea products remain substitutes.
The product’s revenue ceiling is therefore linked to treated pediatric prevalence, not the entire sickle cell population.
Patient and prescribing dynamics
Hydroxycarbamide is a long-established disease-modifying treatment. Its clinical value is recognized in major sickle cell treatment guidelines, but real-world use has historically been limited by adherence, monitoring requirements, clinician practice variation, and concerns about toxicity management.
XROMI addresses the administration barrier. A liquid formulation allows clinicians to titrate doses by weight and may reduce the need for capsule manipulation. That advantage is strongest in younger children and in households where liquid administration improves adherence.
The product does not eliminate the need for routine blood monitoring. Hydroxycarbamide therapy requires specialist supervision because of potential myelosuppression and other adverse effects.
What is the financial trajectory of XROMI?
Public sources do not disclose XROMI-specific revenue, gross margin, EBITDA, prescription volume, or profitability. The most defensible financial assessment is therefore qualitative.
| Financial driver |
Expected effect on XROMI |
| Pediatric sickle cell diagnosis |
Positive |
| Increased hydroxycarbamide adoption |
Positive |
| Liquid formulation demand |
Positive |
| Generic hydroxycarbamide availability |
Negative |
| Extemporaneous compounding |
Negative |
| Reimbursement restrictions |
Negative |
| Lack of U.S. approval |
Negative |
| Specialist distribution model |
Limits scale |
| Orphan and pediatric positioning |
Supports pricing and access discussions |
| Manufacturing scale |
Potential margin constraint |
XROMI likely has a modest absolute revenue profile compared with branded sickle cell medicines used across adult and pediatric populations. Its commercial economics may still be attractive if manufacturing costs are controlled and reimbursement supports a premium over generic capsules or compounded liquids.
A small specialist product can generate stable cash flow when it has recurring pediatric demand, low promotional requirements, and limited direct competition. Its growth rate is more likely to depend on penetration and treatment persistence than on price increases.
What could improve revenue?
Revenue growth would be supported by:
- Broader adoption of hydroxycarbamide in pediatric sickle cell care.
- Increased diagnosis in underserved populations.
- Inclusion in national treatment pathways.
- Reimbursement of the licensed liquid formulation rather than compounded alternatives.
- Distribution expansion into additional European markets.
- Evidence showing improved adherence, dose accuracy, or treatment persistence.
What could reduce revenue?
Downside risks include:
- Hospital pharmacies compounding lower-cost liquid hydroxyurea.
- Generic manufacturers offering alternative pediatric formulations.
- Budget controls that reimburse only the lowest-cost hydroxycarbamide option.
- Slow pediatric treatment initiation.
- Manufacturing interruptions affecting a small specialist supply chain.
- Clinical preference for established capsule products in older children.
What patents protect XROMI?
XROMI’s commercial protection appears to rely more heavily on regulatory authorization, formulation know-how, manufacturing controls, and market access than on a clearly disclosed blocking patent estate.
Hydroxycarbamide is an old active ingredient. Composition-of-matter patent protection for the molecule is not commercially relevant. Any patent value would more likely relate to:
- The oral solution formulation.
- Concentration and excipient selection.
- Chemical stability.
- Dosing methods for pediatric sickle cell patients.
- Container and dosing-device configuration.
- Manufacturing and quality-control processes.
Public regulatory records do not provide a complete patent schedule for XROMI. The absence of a visible patent listing is commercially significant because it reduces the likelihood of a long, patent-driven exclusivity period comparable with a new molecular entity.
What formulations are protected by XROMI?
The principal differentiator is the 100 mg/mL oral liquid formulation. Its commercial value lies in pediatric usability, dose flexibility, and the ability to provide a standardized licensed product instead of a pharmacy-compounded preparation.
Formulation protection, if available in a relevant jurisdiction, would likely be narrower than molecule-level protection. A competitor could potentially design around specific excipients, concentrations, packaging, or manufacturing parameters while retaining the same active ingredient.
When does XROMI lose exclusivity?
XROMI does not have the exclusivity profile of a newly approved innovative drug. Hydroxycarbamide is an established generic active ingredient, and the product’s market protection depends on the specific jurisdiction, regulatory history, orphan status, pediatric provisions, formulation rights, and any enforceable patents.
No single global XROMI patent expiration date is established by the public regulatory information cited here. The relevant dates are jurisdiction-specific:
| Protection category |
XROMI position |
| New chemical entity protection |
Not applicable |
| Basic hydroxycarbamide patent |
Expired or commercially irrelevant |
| Formulation patents |
No complete public schedule identified |
| Orphan exclusivity |
May apply in specific European regulatory contexts, subject to local rules |
| Pediatric regulatory protection |
Potentially relevant, depending on authorization history |
| Data and market exclusivity |
Depends on jurisdiction and authorization pathway |
| U.S. exclusivity |
No U.S. XROMI approval identified |
A competitor would face fewer barriers from molecule patents than from regulatory approval, product quality, supply reliability, reimbursement, and specialist prescribing relationships.
Are there Paragraph IV challenges to XROMI?
No publicly identified U.S. Paragraph IV litigation is associated with XROMI in the regulatory record reviewed. The primary reason is that XROMI does not appear to have a U.S. FDA approval and corresponding Orange Book listing.
What is the Orange Book status of XROMI?
XROMI has no established U.S. Orange Book status based on the cited FDA sources. It is therefore not positioned as a U.S. reference-listed drug for an abbreviated new drug application challenge.
This sharply reduces the relevance of U.S. Paragraph IV strategy. In Europe and the United Kingdom, competitive entry would instead proceed through local marketing authorization, hybrid applications, national procedures, or other applicable regulatory routes.
What patent litigation affects XROMI?
No major publicly reported patent litigation involving XROMI was identified in the cited sources. The litigation risk appears lower than for high-value branded sickle cell medicines with extensive U.S. patent estates.
The more realistic disputes would involve:
- Reimbursement or tender decisions.
- Trademark or branding conflicts.
- Supply and manufacturing contracts.
- Formulation or device patents in individual jurisdictions.
- Regulatory challenges involving therapeutic equivalence or product quality.
The absence of reported litigation does not create a legal exclusivity guarantee. It indicates that XROMI has not generated the type of high-value U.S. patent dispute commonly associated with major branded products.
Which companies are challenging XROMI?
The competitive threat comes less from a single named challenger and more from product categories:
| Competitor category |
Threat to XROMI |
| Generic hydroxyurea capsules |
High for older children and adults |
| Hospital-compounded hydroxycarbamide liquid |
High where reimbursement favors low cost |
| Other licensed oral liquid formulations |
High if widely distributed |
| Sickle cell disease disease-modifying drugs |
Indirect, through treatment substitution |
| Curative or potentially curative therapies |
Long-term strategic threat |
| Supportive care alone |
Limits treatment penetration |
Competing branded sickle cell therapies, including voxelotor historically and crizanlizumab, operate through different mechanisms and do not directly replace hydroxycarbamide in every patient. Their availability can change treatment sequencing, but XROMI remains positioned as a pediatric hydroxycarbamide formulation.
Gene therapies and hematopoietic stem-cell transplantation represent a longer-term threat to chronic drug treatment for selected patients. Their high cost, specialist infrastructure requirements, and eligibility limitations make them unlikely to eliminate near-term demand for XROMI.
How strong is the XROMI patent estate?
The patent estate appears commercially moderate to weak relative to innovative branded pharmaceuticals, but the product may retain practical barriers to substitution.
Strengths
- Pediatric liquid formulation addresses a specific administration need.
- Specialist prescriber relationships can support recurring demand.
- Manufacturing quality requirements may discourage small competitors.
- Orphan and pediatric regulatory positioning can support reimbursement discussions.
- A licensed product may be preferred over pharmacy-compounded alternatives.
Weaknesses
- The active ingredient is old and widely available.
- Generic hydroxycarbamide alternatives exist.
- Publicly visible patent coverage is limited.
- No U.S. regulatory franchise has been established.
- Formulation claims, if present, may be design-around targets.
- The patient population is geographically concentrated.
XROMI’s effective moat is therefore operational and clinical rather than primarily patent-based.
What licensing deals and partnerships affect XROMI?
Publicly available information does not establish a major global licensing transaction comparable with the licensing deals associated with large commercial pharmaceutical assets. XROMI’s market structure appears more consistent with regional commercialization, specialist distribution, and local marketing authorization arrangements.
Potential transaction value would depend on:
- Rights by country.
- Remaining regulatory exclusivity.
- Manufacturing transferability.
- Existing reimbursement status.
- Pediatric prescriber adoption.
- Supply-chain reliability.
- The ability to extend the formulation into additional markets.
A buyer would likely value XROMI as a niche specialty product with recurring demand, not as a platform asset or broad franchise anchor.
How does XROMI compare with other sickle cell drugs?
| Product or category |
Mechanism or role |
Pediatric liquid advantage |
Market position |
| XROMI |
Hydroxycarbamide oral solution |
Yes |
Specialist pediatric formulation |
| Generic hydroxyurea capsules |
Hydroxycarbamide |
No |
Low-cost standard therapy |
| Crizanlizumab |
Anti-P-selectin therapy |
No |
Different administration and treatment role |
| Voxelotor |
Hemoglobin oxygen-affinity modifier |
Product-specific |
Different mechanism; commercial status changed after withdrawal |
| Gene therapy |
Autologous genetic treatment |
No |
High-cost, limited eligible population |
| Compounded hydroxycarbamide liquid |
Hydroxycarbamide |
Yes |
Direct practical substitute |
XROMI’s main competitive comparison is not with gene therapy or biologics. It is with generic hydroxycarbamide and compounded liquid products. The product wins when dosing convenience, quality assurance, and reimbursement outweigh price differences.
What generic launch risks exist for XROMI?
The generic launch risk is structurally meaningful because the active ingredient is off-patent. A competitor would still need to demonstrate pharmaceutical quality, stability, dosing accuracy, and regulatory compliance for the liquid formulation.
The most likely entry scenario is regional rather than global:
- A generic manufacturer obtains authorization for a hydroxycarbamide oral solution.
- National payers apply substitution or price pressure.
- Hospitals and specialist centers compare licensed product quality with compounding economics.
- XROMI retains share among prescribers prioritizing established supply and pediatric dosing tools.
A generic liquid could reduce price and market share without eliminating XROMI. The commercial impact would depend on whether payers mandate substitution and whether the entrant can maintain reliable supply.
What is the long-term outlook for XROMI?
XROMI has a defensible niche but limited blockbuster potential. Its most likely trajectory is stable or moderately growing specialty revenue, supported by pediatric sickle cell prevalence and demand for liquid dosing. Rapid expansion would require broader geographic authorization, stronger reimbursement, or evidence that the product materially improves adherence and treatment outcomes.
The product’s principal risks are generic substitution, compounding, limited U.S. access, and the absence of a clearly disclosed long-duration patent estate. Its principal value is practical: it converts a difficult pediatric dosing problem into a standardized commercial product.
Key Takeaways
- XROMI is a 100 mg/mL hydroxycarbamide oral solution for pediatric sickle cell anemia.
- Its commercial opportunity is concentrated in specialist pediatric hematology.
- Standalone revenue and profitability are not publicly disclosed.
- The product has no established U.S. FDA approval or Orange Book listing in the cited records.
- No major Paragraph IV challenge or patent litigation was identified.
- The principal competitive threats are generic hydroxycarbamide and compounded liquid formulations.
- XROMI’s moat is based on formulation usability, regulatory quality, supply reliability, and specialist adoption.
- The patent position appears less important than market access and manufacturing execution.
- The likely financial profile is niche, recurring, and potentially stable, but not comparable with large branded sickle cell franchises.
- Long-term growth depends on pediatric treatment uptake, reimbursement, and geographic expansion.
FAQs About XROMI Market and Exclusivity
Is XROMI a generic drug?
XROMI contains the generic active ingredient hydroxycarbamide, but it is a branded, licensed pediatric oral solution. Its commercial differentiation is the formulation and regulatory quality rather than a new molecule.
Can pharmacies compound a cheaper alternative to XROMI?
Some healthcare systems may use compounded hydroxycarbamide liquids. Whether compounding is permitted, reimbursed, or preferred depends on national rules, hospital policy, quality requirements, and product availability.
Does XROMI have orphan-drug protection?
XROMI has been associated with orphan and pediatric regulatory positioning in European records. The practical duration and scope of any exclusivity depend on the jurisdiction and the specific authorization basis.
Is XROMI available in the United States?
No U.S. FDA approval for XROMI was identified in the cited records. U.S. patients may receive other hydroxyurea products, but those products are not equivalent to U.S. marketing authorization for XROMI.
Could gene therapy eliminate the market for XROMI?
Gene therapy may reduce chronic drug use for selected eligible patients, but high cost, conditioning requirements, specialist capacity, and patient eligibility limits make broad displacement unlikely in the near term.
References
-
European Medicines Agency. (n.d.). Xromi: Hydroxycarbamide product information and regulatory documentation. https://www.ema.europa.eu/
-
Medicines and Healthcare products Regulatory Agency. (n.d.). Medicines information and United Kingdom product authorization records. https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
-
National Heart, Lung, and Blood Institute. (2014). Evidence-based management of sickle cell disease: Expert panel report, 2014. National Institutes of Health. https://www.nhlbi.nih.gov/health-topics/evidence-based-management-sickle-cell-disease
